Abstract
Historically, renal dysfunction has been considered separately from the cardiovascular risk profile, and has been treated as such. In particular, cardiologists, concerned with treating the heart and vasculature, did not routinely consider the impact of disturbed renal function on the progression toward cardiac events. However, the landscape of cardiovascular disease has changed dramatically in recent years, most notably with the publication in 2003 of a joint statement by a panel of cardiologists and nephrologists illustrating the importance of kidney disease as a risk factor for the development of cardiovascular disease [1]. Recent evidence clearly showed that both microalbuminuria and glomerular filtration rate (GFR), even in the very earliest and otherwise asymptomatic stages of renal disease, are risk factors for cardiovascular disease, and there are numerous links between renal dysfunction and other common risk factors.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154–2169
Hillege HL, Janssen WM, Bak AA et al (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and car diovascular morbidity. J Intern Med 249:519–526
Elliott WJ (2000) Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2:402–411
Brenner BM, Cooper ME, Zeeuw D (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869
Lewis EJ, Hunsicker LG, Clarke WR (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860
Keane WF, Brenner BM, Zeeuw D (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499–1507
Lindholm LH, Ibsen H, Dahlof B (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004–1010
Julius S, Kjeldsen SE, Weber M (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031
Granger CB, McMurray JJ, Yusuf S et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776
Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672–678
Kidney’ Disease Outcomes Quality Initiative (K/DOQI) (2004) K-DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(Suppl 1):S1–S290
Adamczak M, Gross ML, Krtil J et al (2003) Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14:2833–2842
Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878
Aranda P, Aranda FJ, Frutos MA et al (2004) Comparative long-term renoprotective effects of usual versus high dose of telmisartan in nondiabetic nephropathies. J Hypertens 22(Suppl 2):S81–S82
Andersen S, Brochner-Mortensen J, Parving HH (2003) Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 26:3296–3302
Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1944–1951
Dickstein K, Kjekshus J (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial — Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:752–760
Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587
Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675
Pfeffer MA, Swedberg K, Granger CB et al (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759–766
Pfeffer MA, McMurray JJ, Velazquez EJ et al (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906
Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752
McMurray JJ, Ostergren J, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767–771
Yusuf S, Pfeffer MA, Swedberg K et al; CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781
de Zeeuw D, El Nahas AM (2005) Albuminuria, a new target for therapy: treat the kidney to protect the heart. In: El Nahas AM (ed) Kidney Diseases in the Developing World and Ethnic Minorities. Marcel Dekker, New York
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Italia
About this paper
Cite this paper
Borghi, C., Manca, M. (2007). New Evidence about the Beneficial Effects of Angiotensin-Receptor Blockers on the Heart and the Kidney. In: Gulizia, M.M. (eds) Current News in Cardiology. Springer, Milano. https://doi.org/10.1007/978-88-470-0636-2_53
Download citation
DOI: https://doi.org/10.1007/978-88-470-0636-2_53
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0635-5
Online ISBN: 978-88-470-0636-2
eBook Packages: MedicineMedicine (R0)